Recombinant Factor VIII Half-Life Extension via Loop Insertion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemophilia A and B require frequent intravenous administration of plasma-derived or recombinant Factor VIII and Factor IX proteins, which are painful and inconvenient due to their short half-life, leading to challenges in managing bleeding disorders effectively.
Innovation Solution
Development of a recombinant Factor VIII protein with a heterodimer structure comprising specific polypeptide domains and heterologous moieties inserted into permissive loops or the A3 region, enhancing its half-life, stability, and procoagulant activity, allowing for less frequent administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If plasma-derived or recombinant Factor VIII and Factor IX proteins are used for hemophilia treatment, then bleeding disorders can be treated, but frequent intravenous administration is required due to short half-life
Solution Approach 1:
The patent modifies the molecular structure of Factor VIII by inserting heterologous moieties (such as Fc regions, albumin-binding peptides, or other protein segments) into specific domains (A1, A2, or A3) to change its pharmacokinetic parameters. These insertions extend the half-life from hours to days, enabling less frequent administration while maintaining therapeutic effectiveness.
Solution Approach 2:
The invention creates composite Factor VIII proteins by fusing Factor VIII with heterologous protein segments. The resulting chimeric proteins combine the hemostatic function of Factor VIII with the extended half-life properties of the heterologous moieties, achieving both treatment effectiveness and prolonged duration of action.
2Reliability
If frequent intravenous administration is performed to maintain therapeutic levels, then bleeding episodes can be prevented, but patient convenience and quality of life deteriorate
Solution Approach 1:
By extending the half-life parameter through protein modification, the treatment regimen transitions from frequent (multiple times per week) to less frequent (monthly or bi-monthly) administration, significantly improving patient convenience and quality of life while maintaining reliable prevention of bleeding episodes.
3Duration of action of moving object
If heterologous moieties are inserted into Factor VIII to extend half-life, then administration frequency can be reduced, but protein structure complexity increases
Solution Approach 1:
The patent applies local modifications by inserting heterologous moieties into specific permissive loops (A1-1, A1-2, A2-1, A2-2, A3-1, or A3-2) rather than uniformly modifying the entire protein. This localized approach extends half-life while minimizing disruption to the overall protein structure and function.
Solution Approach 2:
The Factor VIII protein is divided into functional domains (A1, A2, A3, B, C1, C2) with specific permissive loops identified in each domain. Heterologous moieties are inserted into these segmented regions, allowing systematic modification of the protein structure to achieve extended half-life with controlled structural changes.
Data Source
AI summary
Provided are recombinant Factor VIII proteins, e.g., human Factor VIII proteins with heterologous moieties inserted into flexible permissive loops located in the Factor VIII A domains, while retaining the procoagulant activity of Factor VIII.